Mixed Urinary Incontinence

0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Amber Therapeutics
1 program
Pudendal neuromodulationN/A1 trial
Active Trials
NCT06885931RecruitingEst. Aug 2029

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
Amber TherapeuticsPudendal neuromodulation

Clinical Trials (1)

NCT06885931Amber TherapeuticsPudendal neuromodulation

Augmenting Urinary Reflex Activity Study 4 (Including eXtended Indications)

Start: Jun 2025Est. completion: Aug 2029
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space